BOSTON, May 8, 2023 - Remedium Bio, is excited to announce that the company has been invited to present at the 2023 FalconX Accelerator Technology Day, taking place May 19th at the Meta Platforms Headquarters in Menlo Park, California. This year’s FalconX Accelerator event is an exclusive invitation only event showcasing the most innovative companies across Technology and Healthcare. Remedium will provide an overview of its innovative dose adjustable gene therapy platform technology for the improved delivery of subcutanously administered biologics.

“We are extremely excited to have the opportunity to present Remedium at this invitation only event organized by the FalconX Accelerator team” said Frank Luppino, President and CEO of Remedium, “The invitation to present Remedium’s gene therapy platform highlights the transformational nature of this technology, which is potentially capable of replacing subcutaneous protein therapies as a treatment modality, at a fraction of the current development and treatment costs”.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, May 1, 2023 - Remedium Bio, a biotechnology company developing advanced therapies in the fields of rheumatology, endocrinology, and neurology, today announced the acceptance of an abstract entitled “FGF18 Gene Therapy Treatment for Osteoarthritis Promotes Regenerative Chondroanabolic and Anti-Catabolic Activity” for the 8th Annual Skeletal Research Symposium (ASRS). This year’s ASRS will take place on May 8th, in Boston, as a live in-person event at the Mass General Hospital (MGH) Main Campus. The work presented will highlight Remedium’s progress in the development of a novel potentially disease modifying treatment for Osteoarthritis, which is based on the chondrogenic mechanism of FGF18. The abstract will highlight the latest safety, efficacy, durability, and mechanistic findings from the preclinical studies comparing a single injection FGF18 gene therapy treatment to a series of protein injections and a placebo control.

“We are very excited for the opportunity to present our work at the 8th Annual Skeletal Research Symposium” said Frank Luppino, President and CEO of Remedium, “The acceptance of our abstract for this prestigious, MGH-organized event, highlights the advances made by the team on the development of Remedium’s first-in-class potentially disease modifying gene therapy for Osteoarthritis”.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Apr 10, 2023 - Remedium Bio, a biotechnology company developing advanced therapies in the fields of rheumatology, endocrinology, and neurology, today announced the acceptance of an abstract entitled “Treatment with rhFGF18 Analog Results in Cerebroprotection and Recovery of Motor and Memory Function in a Rat Model of Acute Ischemic Stroke” for the 2023 American Academy of Neurology (AAN) annual meeting. This year’s AAN will take place in Boston, Massachusetts April 22nd through the 27th as a live in-person or virtual online event. The work presented will highlight Remedium’s progress in the development of a novel treatment for ischemic stroke. The American Academy of Neurology is a professional, scientific, and medical society established in 1948 with a current membership of over 38,000 scientists and clinical researchers representing the fields of neurology, neuroimmunology, and neural genetics.

“We are honored to have been accepted to present our abstract reviewing the progress made to date in the development of our innovative treatment for the management of ischemic stroke at 2023 AAN” said Frank Luppino, President and CEO of Remedium, “The acceptance of our abstract at such a prestigious conference highlights the advances made by the team on the development of Remedium’s innovative pipeline of disease modifying therapies”.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Apr 5, 2023 - Remedium Bio is pleased to announce the appointment of Charles Sherwood, Ph.D., as a Corporate Advisor for the company. Dr. Sherwood brings a wealth of experience building companies that have created significant value developing products for Osteoarthritis and cartilage regeneration. Dr. Sherwood will advise on corporate strategy and the company’s lead candidate disease modifying gene therapy for Osteoarthritis.

Dr. Sherwood is the Founder of Sherwood Ventures, a firm focused on early-stage life science company investments. Dr. Sherwood was previously the CEO of Anika Therapeutics, a global, publicly traded regenerative medicine company engaged in the discovery, preclinical and clinical development, approval, and commercialization of restorative and regenerative treatments, with a focus in Rheumatology. Dr. Sherwood brought to the market leading OA palliative therapies including Monovisc®, Orthovisc®, and Cingal®. In addition, he led the development and industrialization of Hyalofast®, a single-step cartilage regenerative solution for focal cartilage defects. Under his leadership, the OA-focused company with a $6M market cap grew to a highly-profitable multinational corporation with a distribution network in over 85 countries.

"We are extremely excited to onboard Dr. Sherwood in this important advisory role at this transformational inflection point for Remedium” said Frank Luppino, President and CEO of Remedium Bio. “We look forward to levering Dr. Sherwood’s deep experience and business expertise in rheumatology, product development, and strategic partnering as we continue to advance our lead disease-modifying Osteoarthritis product and novel platform technology”.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Mar 22, 2023 - Remedium Bio, a biotechnology company developing a lead candidate disease modifying treatment for Osteoarthritis (OA), and Exothera S.A., a full-service Contract Development and Manufacturing Organization (CDMO) specialized in gene therapy, vaccines, and oncolytic viruses, reached an agreement for a collaboration to demonstrate the industrialization potential of Remedium’s AAV2-FGF18.

Remedium’s lead candidate is the only disease modifying gene therapy based on the clinically proven regenerative mechanism of FGF18. OA is the largest unmet clinical need in rheumatology, with no currently approved disease modifying treatments and an estimated 300-500 million patients around the globe. Remedium’s recent development progress, demonstrating strong safety and efficacy potential in a translatable preclinical model, was recently presented at the 2023 Orthopaedic Research Society meeting, 2023 OARSI World Congress, and the 2022 American Society for Bone and Mineral Research meeting.

Exothera is a highly experienced viral vector manufacturer, with demonstrated capabilities in large-scale AAV production, achieving state-of-the art titers and quality. Boasting an existing 160,000 sq. ft. high-tech manufacturing centre of excellence in Jumet, Belgium, Exothera is well-positioned to supply Remedium's lead candidate for clinical studies and at commercial scale. Exothera can count on state-of-the-art technology and an extensive set of experts in AAV-based viral vector production. The CDMO will execute a proof of concept for transient expression of Remedium’s AAV2-FGF18 with suspension culture, based on a HEK-293 cell line. Exothera will focus on identifying a high yield production process and reduce cost of goods for the manufacturing process of Remedium’s AAV2-FGF18.

Hanna Lesch, Chief Technology Officer at Exothera: “It is wonderful to engage in a new challenge to apply the exoREADY™ platform to a first-in-class gene therapy for Osteoarthritis. We have already achieved promising results with other AAV-based gene therapies, and we are confident that we can play our part in making a better life for patients”.

Frank Luppino, President, and CEO of Remedium: “With several recently approved cell and gene therapy products advancing to the market, gene therapy is transcending the realm of rare monogenic disorders to enable treatment of large unmet clinical needs like Osteoarthritis. Remedium’s recently published preclinical results uniquely position the company to advance this transformative therapy to the clinic. We are very excited to be able to partner with Exothera on this project to advance our lead candidate through preclinical toxicology studies and eventually human clinical trials.”

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Mar 16, 2023 - Remedium Bio, a Boston-area gene therapy company developing treatments for a range of large clinical unmet needs in rheumatology, endocrinology, and age-related diseases, and Biovian Oy, a globally operating Nordic CDMO for biopharmaceuticals, have agreed on a collaboration for AAV drug development. The agreement covers Remedium’s lead candidate, a first-in-class disease-modifying treatment for Osteoarthritis (OA) under the name RMD 1101. Biovian has agreed to include Remedium’s lead candidate in Biovian’s AAV manufacturing platform development program. Biovian’s second-generation AAV platform will be built around a selected high-productivity and state-of-the-art quality suspension-based HEK293 cell line, with full scalability to 200L and utilizing chromatography for standard purification. Biovian has invented a robust way to efficiently separate full capsids from empty capsids, applicable to large-scale manufacturing.

Antti Nieminen, CEO at Biovian: "We are pleased to start a collaboration with Remedium Bio and to include Remedium’s AAV candidate in our ongoing second-generation AAV platform development program. Remedium’s therapeutic candidate will be important in the validation of Biovian’s second generation AAV platform – bringing a new level of quality and efficiency to the viral vector manufacturing space”.

Frank Luppino, President and CEO at Remedium Bio: “Having recently generated one of the most comprehensive preclinical efficacy datasets in Osteoarthritis and presented at the 2023 Orthopedic Research Society meeting, we are extremely excited to scale production of our lead candidate RMD1101 to support Toxicology and Clinical demand. Partnering with Biovian’s high-productivity viral vector manufacturing process will enable clinical supply and cost-effective production at eventual commercial scale for a disease that impacts hundreds of millions of people around the globe.”

About Biovian

Biovian is a Contract Development and Manufacturing Organization, CDMO that provides premium services to biotech companies developing innovative gene therapies and biopharmaceuticals. The goal of the company is to turn ideas into products by taking client projects from the laboratory bench to the clinic. Biovian offers its clients One-Stop-Shop GMP CDMO services, with modularity available from gene to finished vial. Biovian is especially focusing on viral vector production and microbial production of recombinant proteins and GMP plasmid DNA. Guided by its Nordic ethos Biovian has established a reputation for delivering high-quality work on time and within budget to a global client base. Additional information is available at www.biovian.com.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Mar 13, 2023 - Remedium Bio, a gene therapy company developing novel treatments for significant unmet needs, today announced the publication of pre-clinical data demonstrating the safety and chondrogenic activity of RMD1101, its innovative gene therapy for Osteoarthritis. These data are the first to be published from Remedium’s ongoing research collaboration with Tufts University studying the approach. The paper, entitled “Adeno-Associated Virus-Delivered Fibroblast Growth Factor 18 Gene Therapy Promotes Cartilage Anabolism” will be published in Volume 14, Issue 1 of the journal Cartilage, and is available OnlineFirst.

Key Points

- AAV2-FGF18 appears to have a wide therapeutic safety window and is able to induce chondrogenesis at very low, locally administered doses

- The FGF18 gene therapy appears to induce chondrogenesis by increasing hyaline cartilage associated gene expression and promoting chondrocyte proliferation

- RMD1101 appears safe and effective at promoting cartilage anabolism in vivo, following a single intra articular injection

“Having these results published in Cartilage provides important external validation of their significance” said Frank Luppino, President and CEO of Remedium. “Our findings confirm the chondrogenic mechanism after a single injection of RMD1101 and provide preliminary confirmation for the potential of the gene therapy approach to treating Osteoarthritis.” RMD1101 is the only disease modifying gene therapy treatment for Osteoarthritis based on the clinically validated chondrogenic mechanism of FGF18. It is being studied as a single injection treatment for OA in both the human and companion animal markets. “Our results show the promise of treating Osteoarthritis by harnessing the endogenous regenerative power of articular cartilage with a single intra-articular injection FGF18 gene therapy,” said Dr. Li Zeng, PhD, Associate Professor of Immunology at Tufts University School of Medicine. Dr. Zeng is a co-author of the publication and an expert in Osteoarthritis and the molecular and cellular mechanisms of the disease.

Cartilage is a peer-reviewed, open access journal which publishes articles with a focus on recent discoveries related to the musculoskeletal system and cartilage repair, development, and regeneration. The Sage Publishing group, MEDLINE indexed journal publishes full length original manuscripts covering preclinical and clinical research, and is considered among the top journals in the field of cartilage regeneration.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Feb 6, 2023 - Remedium Bio, a biotechnology company developing a lead candidate disease modifying treatment for Osteoarthritis (OA), today announced the acceptance of an abstract titled “AAV2-FGF18 Repairs Cartilage in Disease Model of Osteoarthritis” for the 2023 Tissue Engineering Strategies for Human Health and Longevity conference. This year’s event will take place at the Marriott Copley Place in Boston as a live, in-person meeting. The work presented will highlight Remedium’s progress in the development of a novel gene therapy for the treatment of OA, a single-injection treatment potentially capable of reversing cartilage loss in OA. The Tissue Engineering and Regenerative Medicine International Society (TERMIS) is a professional, scientific, and medical society with a mission of advancing tissue engineering and regenerative medicine to generate knowledge with a view to improving patient outcomes.

“We are honored to have been accepted to present our abstract reviewing the progress made to date in the development of our FGF18 gene therapy treatment for Osteoarthritis at the 2023 Boston TERMIS” said Frank Luppino, President and CEO of Remedium, “We are excited to share the recently generated preclinical safety and efficacy data highlighting the regenerative potential of RMD1101 in the treatment of a range of cartilage pathologies”.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Jan 10, 2023 - Remedium Bio, announces the acceptance of an abstract titled “Novel AAV2-FGF18 Gene Therapy Promotes Cartilage Anabolism” for Podium Presentation at the 50th Annual Veterinary Orthopedic Society (VOS) Conference. This year’s VOS will take place Mar 11-18th at Big Sky, Montana bringing together academics, researchers, and veterinarians to discuss the latest discoveries in veterinary orthopedics, traumatology, and regenerative medicine. The research presented will provide an overview of Remedium’s progress in the development of a novel, potentially disease modifying gene therapy for the treatment of Osteoarthritis, and its advantages specifically for veterinary medicine.

VOS is the leading veterinary medicine society focused on orthopedics and osteoarthritis, having provided a podium for the presentation of veterinary orthopedic discoveries for over 50 years. The VOS abstracts are published in the Veterinary and Comparative Orthopaedics and Traumatology (VCOT) Journal and made available online at the Veterinary Orthopedic Society website. “We are very excited to have been accepted to present our abstract reviewing veterinary medicine potential of our first-in-class chondrogenic gene therapy treatment for Osteoarthritis at the 2023 VOS” said Frank Luppino, President and CEO of Remedium; “The selection of our abstract for a podium presentation is an important milestone highlighting the progress we have made to date developing this novel treatment and its significant translational potential for the treatment of companion animals”.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Dec 6, 2022 - Remedium Bio, a biotechnology company developing a lead candidate disease modifying gene therapy for the treatment of Osteoarthritis (OA) announced today the acceptance of an abstract titled “Novel AAV2-FGF18 Chondrogenic Gene Therapy” for the 2023 Osteoarthritis Research Society International (OARSI) conference. The 2023 OARSI World Congress on Osteoarthritis will take place March 17th through 20th in Denver Colorado. The studies presented will provide an overview of Remedium’s progress in the development of a novel gene therapy for the treatment of Osteoarthritis, highlighting the potential of the company’s first-in-class chondrogenic gene therapy treatment.

OARSI is a leading international medical society for the advancement of understanding, early detection, treatment, and prevention of Osteoarthritis – a highly debilitating disease affecting more than 600 million people worldwide. For over 30 years, OARSI brings together scientists and engineers at the annual World Congress on Osteoarthritis. All abstracts presented at the Congress are published in the supplement to OARSI’s journal, Osteoarthritis and Cartilage. “We are very excited to have been accepted to present our abstract reviewing the safety and efficacy of our first-in-class chondrogenic gene therapy treatment for Osteoarthritis at the 2023 OARSI” said Frank Luppino, President and CEO of Remedium; “The selection of our abstract for a podium presentation is an important milestone highlighting the progress we have made to date developing this novel treatment”.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Dec 1, 2022 - Remedium Bio is pleased to announce that the company will be attending BioFIT 2022, taking place in Strasbourg, France, on November 29-30th and virtually December 7-8th, 2022. BioFIT is Europe’s leading tech transfer and innovation sourcing event and a premier marketplace for Life Science investments. With over 1000 delegates in attendance from 35 countries, the conference and matchmaking forum are a unique opportunity to highlight Remedium’s lead candidate disease modifying gene therapy for Osteoarthritis and R&D pipeline.

“We were extremely pleased to have been selected to present at least year’s event and are excited to be back in attendance in 2022" said Frank Luppino, President and CEO of Remedium. "Biofit 2022 is particularly suited to Remedium’s pipeline, with a focus on novel therapeutics as well as a dedicated track focused exclusively on Animal Health innovation". At the 2022 BioFIT, Remedium will highlight its lead candidate disease modifying gene therapy for Osteoarthritis and the Animal Health rheumatology pipeline.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Nov 15, 2022 - Remedium Bio, a biotechnology company developing a lead candidate disease modifying gene therapy for the treatment of Osteoarthritis (OA) announced today the acceptance of an abstract titled “AAV2-hFGF18 Increases Cartilage Thickness and Promotes Hyaline Cartilage Anabolism” for the Orthopedic Research Society (ORS) Conference. The 2023 ORS meeting will take place February 10th through 14th in Dallas Texas. Remedium’s abstract was selected to be presented at the Podium Spotlight Session on February 13th, highlighting therapeutic delivery to joints. The work presented will review Remedium’s progress in the development of a novel gene therapy for the treatment of OA, which is the only single-injection treatment potentially capable of reversing cartilage loss, based on the clinically proven mechanism of FGF18.

Dating back to 1954, the Orthopedic Research Society is a global organization focused on musculoskeletal research. Today, the ORS consists of over 4000 members in nearly 50 countries, representing researchers, clinicians, and veterinarians. “We are very excited to have been accepted to present our abstract reviewing the progress made to date in the development of our FGF18 gene therapy treatment for Osteoarthritis at the 2023 ORS” said Frank Luppino, President and CEO of Remedium; “The selection of our abstract for a podium presentation spotlight session is an important milestone highlighting the progress we have made to date”.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Nov 8, 2022 – Remedium Bio, Inc., a biotechnology company developing novel gene therapies for large unmet needs, today announced the appointment of Richard Hague to its Board of Directors. Mr. Hague is an accomplished biotechnology executive with extensive multi-discipline experience in rheumatology and with regenerative therapies. "Richard is a highly valued addition to the Remedium team, and his background and expertise across three decades in the industry, with many successes in osteoarthritis and regenerative medicine, will help guide Remedium’s strategy and portfolio development as we embark on the next phase of our growth” said Frank Luppino, CEO of Remedium. "We welcome Richard to our Board and look forward to his contributions.”

“Since inception, Remedium has rapidly built a strong portfolio of novel gene therapies,” said Mr. Hague. “I am excited to join the Board of Directors at this pivotal stage for the company, and eager to help bring the unique advantages of gene therapy to the treatment of osteoarthritis.”

Mr. Hague is currently the President and Chief Executive Officer of PolarityTE, a regenerative medicine company developing its lead cell therapy product for the treatment of complex wounds. Before joining PolarityTE, Mr. Hague was the Chief Commercial Officer at Anika Therapeutics, where he led all global commercial activities and had oversight of the R&D and Clinical Research functions. He spent a significant portion of his career at Genzyme and later Sanofi (following Sanofi’s acquisition of Genzyme), where he held positions of increasing responsibility, culminating in his role as VP/General Manager of Sanofi’s Cell Therapy and Regenerative Medicine Business Unit. While at Genzyme, Richard played an integral role in the launch and adoption of the first autologous cell therapy products used in orthopedics and burns. Subsequently, he has led the development and launch of innovative products in multiple markets via the CBER and CDRH regulatory pathways.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Oct 20, 2022 – Remedium Bio is excited to announce that the company has been invited to showcase its innovative flagship potentially disease modifying gene therapy for Osteoarthritis at the Canadian Stock Exchange (CSE) Tech Tuesday webinar, October 25th. The Tech Tuesdays webinars are sponsored by the CSE and designed to spotlight up-and-coming public and private companies that are shaking up the technology industry. The upcoming event will focus on innovations in orthopedic medicine and highlight Remedium’s progress on its lead candidate for Osteoarthritis.

“We are very excited to have been invited to present at the CSE’s Tech Tuesday webinar” said Frank Luppino, President and CEO of Remedium Bio. “The event provides an opportunity to showcase our innovative rheumatology portfolio for a new audience interested in cutting edge orthopedic innovation”.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Oct 11, 2022 – Remedium Bio will be attending the 2022 Pharma Partnering Summit, taking place live on November 17th and 18th in Boston, Massachusetts. The Pharma Partnering Summit brings together senior executives focused on licensing, collaboration, fundraising, and investment. Remedium will be highlighting its lead candidate disease modifying therapy for Osteoarthritis, dose-adjustable gene therapy platform technology, and neuroprotective treatment for the prevention of neurodegeneration following ischemic stroke at the Summit.

“We are looking forward to discussing Remedium’s lead candidate and innovative pipeline at the Pharma Partnering Summit” said Frank Luppino, President and CEO of Remedium Bio. “Having advanced our lead candidate disease modifying treatment for Osteoarthritis and pipeline assets through preclinical proof of concept, we are excited about the opportunity to showcase our portfolio to industry leaders, potential partners, and investors”.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Oct 5, 2022 – Remedium is excited to announce that the company has been invited to present at the 2022 Life Sciences Summit, organized by the Center for Biotechnology, Stony Brook University. The Life Sciences Summit is an investor and business development conference showcasing professionally managed, private companies at the Pre-Clinical through Phase-IIa stage of development. The two-day program will feature corporate presentations by promising young companies with transformative science that targets clinical unmet needs. The Showcase Sessions will begin on Oct 17, with the event taking place virtually on November 2nd and 3rd.

“We are honored to have been invited to present at the 2022 Life Sciences Summit for the second year in a row” said Frank Luppino, President and CEO of Remedium Bio. “Having generated in vivo proof of concept data on our lead candidate disease modifying gene therapy for Osteoarthritis, and advanced several pipeline candidates to preclinical efficacy, we look forward to showcasing our progress with industry leaders and investors”.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Sep 26, 2022 - Remedium is pleased to announce that the company has been awarded an honorary membership in the the Entrepreneurs & Professionals in Partnership for Innovation in Healthcare Network, and also selected to present at an EPPIC webinar of both the organization’s members as well as industry professionals. This selection was made by EPPICON judges from over 20 applications for the recent pitch competition at the EPPICON 2022 conference in Santa Clara, CA.

EPPIC is a cross-disciplinary group of healthcare industry leaders, sharing a common vision to bring innovative product to patients and their caregivers through the integration of diverse disciplines and entrepreneurship. Membership in EPPIC brings exclusive benefits including the ability to influence and develop EPPIC's strategic initiatives, as well as access to specialized entrepreneurial content and the broader EPPIC network of investors and industry partners.

“We are very excited to have had the opportunity to present at the 2022 EPPICON and grateful for the award” said Frank Luppino, President and CEO of Remedium Bio. “As we continue to generate promising data for our lead candidate disease modifying gene therapy for Osteoarthritis, the ability to tap into the EPPIC network is an excellent opportunity to further showcase our technology to industry leaders, potential partners, and investors”.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Sep 14, 2022 - Remedium is pleased to announce that the company has been invited to present at the flagship conference of the Entrepreneurs & Professionals in Partnership for Innovation in Healthcare (EPPICON). EPPICON 2022, taking place on September 17th at the Santa Clara Convention Center, brings together leading professionals, investors, and corporations in a forum to discuss state-of-the-art innovation in healthcare.

“We are very excited to have been selected and invited to present Remedium at EPPICON 2022” said Frank Luppino, President and CEO of Remedium Bio. “Having further advanced our lead candidate disease modifying treatment for Osteoarthritis, this conference provides a unique opportunity to showcase our technology to industry leaders, potential partners, and investors”.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Aug 15, 2022 - Remedium Bio, Inc., a biotechnology company developing novel gene therapies, today announced that it has closed more than $2.3M in its expanded seed round financing. Funding from the raise is being used to study Remedium’s lead product, a single-injection gene therapy potentially capable of reversing cartilage loss, in a collaboration with Tufts University School of Medicine scientists researching rheumatic disorders. The financing was led by Sherwood Ventures and included participation from, LongevityTech.Fund, Primo Medical Group, Angel Star Ventures, Apis Health Angels, MicroVentures, and Guindy Alumni Angels.

Remedium’s lead candidate is the only single injection gene therapy based on the clinically proven anabolic mechanism of FGF18, which has demonstrated the ability to reverse cartilage loss in a placebo controlled, multi-center, randomized clinical trial. Osteoarthritis is the largest unmet need in Rheumatology, presenting a market of $37B with no currently approved therapies capable of slowing or reversing disease progression. Remedium’s novel solution offers the potential to arrest disease progression after a single injection and promote restoration of a more natural, youthful phenotype of articular cartilage.

“Our technology has the potential to reverse years of age-related cartilage loss, for a disease that currently has no approved therapeutic treatments capable of slowing or reversing progression” said Frank Luppino, President and CEO of Remedium Bio, Inc. “We are extremely excited about the progress made to date, and believe that our gene-augmentation technology can be translated to a number of other age-related pathologies with no currently available disease-modifying options.”

Remedium was founded by orthopedics industry veterans with proven track records of developing leading therapeutics at companies ranging from start-ups to Fortune 500. Remedium has attracted a number of academic collaborators and medical KOLs to its advisory board including Dr. Timothy McAlindon, MD, MPH, Chief of the Division of Rheumatology at Tufts Medical Center, Professor at Tufts University School of Medicine; Dr. Anastassios Pittas, MD, MS, Chief of the Division of Endocrinology, Diabetes, and Metabolism and Co-Director of the Diabetes and Lipid Center at Tufts Medical Center, Professor at Tufts University School of Medicine; Dr. Jeff Ellsworth, PhD, the pioneer of rhFGF18 technology and CSO of Recardia Therapeutics; Dr. Li Zeng PhD, MA, MS, BA Associate Professor Immunology at Tufts University School of Medicine; and Dr. Kai Zou PhD, Assistant Professor, Department of Exercise and Health Sciences, at the University of Massachusetts, Boston.

Remedium’s pipeline includes therapeutic indications in Osteoarthritis, Diabetes, Stroke, and other large unmet clinical needs.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Aug 8, 2022 - Remedium Bio, a biotechnology company developing a lead candidate disease modifying treatment for Osteoarthritis (OA), today announced the acceptance of an abstract entitled “Characterization of a Novel FGF18 Gene Therapy for the Treatment of Osteoarthritis” for the 2022 Annual American Society of Bone and Mineral Research (ASBMR) meeting. This year’s ASBMR will take place in Austin Texas on September 9th through 12th as an in-person live event. The work presented will highlight Remedium’s progress in the development of a novel gene therapy for the treatment of OA, which is the only single-injection treatment potentially capable of reversing cartilage loss in OA, based on the clinically proven mechanism of FGF18. The American Society for Bone and Mineral Research is a professional, scientific, and medical society established in 1977 with a current membership of over 4,000 worldwide scientists and clinical researchers representing the fields of orthopedics, rheumatology, and pharmacology.

“We are honored to have been accepted to present our abstract reviewing the progress made to date in the development of our FGF18 gene therapy treatment for Osteoarthritis at the 2022 ASBMR” said Frank Luppino, President and CEO of Remedium, “We have been additionally invited to present a plenary poster on the first day of the event and are looking forward to sharing our findings at this prestigious forum”.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Aug 1, 2022 - Remedium Bio is excited to announce that the company has been selected amongst the finalists to present at the Life Science Nation’s RESI Boston Innovator’s Pitch Challenge event. The Redefining Early Stage Investments (RESI) Boston conference will take place September 21-22 at the Westin Copley Place in person, following more than 2 years in digital format. This 2-day event will include participation from over 450 investors and strategic partners, featuring panel discussions, workshops, and culminating in the Pitch Challenge sessions. Remedium will showcase its lead candidate – only single injection gene therapy potentially capable of reversing cartilage loss in Osteoarthritis, based on a clinically proven mechanism.

“We are very excited to have been selected amongst the finalists for this year’s first in-person RESI event in Boston” said Frank Luppino, President and CEO of Remedium Bio. “Having made significant progress on our lead candidate treatment for OA and expanded the R&D pipeline, we now look forward to engaging potential partners and investors following the Pitch Challenge sessions”.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Jul 14, 2022 - Remedium Bio is excited to announce that our President and Chief Executive Officer, Frank Luppino was named as one of 2022's Top 10 Most Inspiring CEOs by the C Level Focus (CLF) magazine. C Level Focus is a London-based global media outlet, with a focus on news and information about business, investing, technology (including Biotech and Life Sciences), entrepreneurship, leadership, and affluent lifestyles.

"I am deeply honored by this recognition and excited to be leading Remedium on its quest to develop therapeutics for a broad range of highly debilitating conditions" said Frank Luppino, President and CEO of Remedium. The article highlights Remedium’s lead candidate gene therapy treatment for Osteoarthritis, a classical disease of aging affecting 1 in 7 adults and comprising a nearly $40 billion dollar market. The article further highlights Remedium's approach to product development using novel, combinatorial modular application of well-characterized technologies, which streamlines the R&D lifecycle, enabling the realization of life-changing medicines more efficiently and effectively.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Jul 12, 2022 - Remedium Bio, a biotechnology company developing innovative gene therapies, today announced the acceptance of an abstract entitled “Novel High Efficiency Gene Delivery System for Human Primary Preadipocytes and Adipocytes” for the presentation of a poster at the 2nd Annual Next Generation Gene Therapy Vectors Summit in Boston. The work presented will highlight Remedium’s progress in the development of a novel gene delivery technology for use in its Type 2 Diabetes program. This technology is being evaluated in a collaboration at the University of Massachusetts Boston, with Professor Kai Zou’s laboratory, and is intended to support a number of therapeutic indications in Remedium’s pipeline.

The 2nd Annual Next Generation Gene Therapy Vectors Summit is taking place in Boston on July 18th to 20th, bringing together C-suite leaders, R&D experts, and Business Development professionals from Boston’s leading pharma and biotech companies. “We are excited to present data highlighting the progress on our gene delivery technology”, said Frank Luppino, President and CEO of Remedium; “The Next Generation Gene Therapy Vectors Summit is an important milestone for Remedium, as this technology potentially enables treatments in a number of therapeutic indications.”

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, May 25, 2022 - Remedium Bio announced today the acceptance of its abstract entitled “Novel FGF-18 Gene Therapy for the Treatment of Osteoarthritis” for presentation of a poster at the 4th Annual Longevity Therapeutics Summit. The poster will present results from preclinical studies of Remedium’s gene therapy for the treatment of Osteoarthritis (OA). FGF18 has been shown to result in structural improvement in OA patients in a Phase 2, placebo controlled, randomized clinical trial. Remedium’s novel gene therapy is a first in class, single-injection, potentially disease-modifying OA treatment, based on the proven chondroregenerative mechanism of FGF-18. Osteoarthritis is the most common form of arthritis and the largest unmet need in rheumatology, affecting an estimated 500 million people worldwide. Currently, there are no approved disease-modifying OA treatments capable of slowing or reversing disease progression.

The Longevity Therapeutics Summit is taking place in San Francisco on Jun 28th to 30th, bringing together over 100 leading biotech and pharma drug developers, academics, and investors. “We are excited to present data demonstrating proof of concept and the potential unique benefits of our novel gene therapy”, said Frank Luppino, President and CEO of Remedium; “The Longevity Therapeutics Summit is an important milestone for Remedium, and is the first in a series of presentations highlighting the encouraging data being generated on our potentially disease modifying treatment for Osteoarthritis.”

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Apr 7, 2022 - Remedium is excited to announce the appointment of Dr. Jeff L. Ellsworth as a scientific advisor for the company’s Rheumatology portfolio. Dr. Ellsworth led the R&D team that originally discovered FGF18’s ability to regenerate cartilage and alleviate infarct-induced injury in an animal model of stroke. He has led several R&D functions at companies including CV Therapeutics, ZymoGenetics, Moderna, and Homology Medicines, and is a renowned authority on Osteoarthritis therapeutics in general and the FGF18 protein specifically. Jeff is also a sought after consultant with a successful track record of providing strategic guidance to emerging biotechnology companies. Jeff holds a PhD in Pharmacology and Cell Biophysics from the University of Cincinnati College of Medicine and a Bachelor of Science in Chemistry from the Indiana University Bloomington. Upon completion of his dissertation defense, Jeff spent a number of years as a post-doctoral fellow at Stanford University School of Medicine researching lipoprotein receptors and lipid metabolism.

"Jeff is a perfect addition to Remedium’s team of advisors given his pivotal role in the discovery of FGF18’s regenerative potential, and strong track record developing a number of highly impactful regenerative therapies" said Frank Luppino, CEO of Remedium Bio. "Jeff will add significant value to Remedium’s R&D activities, including our lead candidate and pipeline products, and we are extremely excited to partner with him.”

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Mar 3, 2022 - Remedium Bio, Inc. is pleased to announce that the company has been accepted into the P4 Precision Medicine Accelerator Program, a collaboration of UCL, London’s Global University, and Capital Enterprise, the UK’s largest startup ecosystem. Remedium has also been accepted into the sister program, P4SY, focused specifically on collaborations in the South Yorkshire region, the location chosen for one of three Gene Therapy Innovation & Manufacturing Centers to be established in the UK to foster advances in precision medicine.

“We are excited to participate in these two accelerator programs” said Frank Luppino, CEO of Remedium Bio. “Accessing this world-class entrepreneurship network and burgeoning gene therapy and precision medicine ecosystem will help Remedium increase awareness of our novel gene therapy pipeline, expand access to potential collaborators, and provide access to a network of potential strategic partners.”

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Feb 24, 2022 - Remedium is excited to announce the appointment of Dr. Li Zeng, Associate Professor of Immunology as a scientific advisor for the company’s Rheumatology portfolio. Dr. Zeng currently holds the position of Associate Professor of Immunology at the Graduate School of Biomedical Sciences at Tufts University. She holds a PhD and MA in Cell & Molecular Biophysics from Columbia University with Postdoctoral training at the Harvard Medical School, an MS in Biochemistry from Tsinghua University, and a BA in Plant Physiology & Biochemistry from the Beijing Agricultural University. Currently, Dr. Zeng leads an integrated research laboratory at the Tufts University, Graduate School of Biomedical Sciences focusing on Osteoarthritis research. Her laboratory has generated high-impact publications in journals including Nature Scientific Reports, Nature Laboratory Investigations, Development, Journal of Clinical Investigations, and Osteoarthritis and Cartilage.

"We are extremely excited to partner with Dr. Li Zeng in this important advisory role, supporting our lead candidate Rheumatology gene therapy" said Frank Luppino, CEO of Remedium Bio. "Dr. Zeng is a world-renowned authority who brings a wealth of scientific and mechanistic knowledge to the company enabling further validation of our potentially disease modifying gene therapy for Osteoarthritis”.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Jan 18, 2022 - Remedium Bio, Inc. is excited to announce that the company is presenting at the VC Fast Pitch Event taking place virtually on January 20th. This year's forum is hosted by BDVP, a premier business accelerator with a network of 13,000 investors and 40,000 business partners. Remedium will showcase its lead candidate disease modifying Osteoarthritis gene therapy, with a focus on the progress made following the initiation of a broad research partnership in October 2021, and highlight recent developments around Remedium's innovative pipeline of gene therapy products.

“We are honored to present at the VC Fast Pitch Event allowing us to showcase Remedium and our innovative pipeline” said Frank Luppino, President and CEO of Remedium Bio. “As we begin generating efficacy data on our single-injection gene therapy treatment for Osteoarthritis, we are now approaching several transformative milestones for the organization, which we will highlight at this forum".

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Jan 10, 2022 - Remedium Bio, Inc., a biotechnology company developing novel gene therapies, is pleased to announce it has entered into a Sponsored Research Agreement with the University of Massachusetts Boston to complete pre-clinical efficacy studies on Type 1 and Type 2 Diabetes pipeline candidates. The collaboration will evaluate platform technology for the treatment of Diabetes, with translational potential to the broader Remedium pipeline of single-injection potentially disease-modifying gene therapies. The research is being led by Dr. Kai Zou, PhD, Assistant Professor at the Department of Exercise and Health Sciences under the Robert and Donna Manning College of Nursing and Health Sciences at the University of Massachusetts Boston. Dr. Zou’s laboratory has expertise in characterizing metabolic dysfunction associated with Diabetes and has extensive know-how in the fields of endocrine dysregulation, insulin resistance, impaired glucose metabolism, and associated molecular pathophysiological mechanisms. Dr. Zou has extensive expertise in endocrinology having generated high-impact publications in journals including the Journal of Physiology, Surgery, Physiological Genomics, and International Journal of Obesity.

“The initiation of this research program is a transformational milestone for Remedium” said Frank Luppino, CEO of Remedium Bio. “Through this partnership, Remedium will expand its development portfolio and validate our gene-therapy dose-adjustment platform, which has broad therapeutic applicability beyond the currently targeted indications”.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.